Interleukin-5 in the Pathophysiology of Severe Asthma

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in physiology Vol. 10; p. 1514
Main Authors Pelaia, Corrado, Paoletti, Giovanni, Puggioni, Francesca, Racca, Francesca, Pelaia, Girolamo, Canonica, Giorgio Walter, Heffler, Enrico
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.12.2019
Subjects
benralizumab
eosinophils
IL-5
mepolizumab
Physiology
reslizumab
T2-high asthma
reslizumab
IL-5
eosinophils
T2-high asthma
benralizumab
mepolizumab
Online AccessGet full text

Cover

More Information
Summary:Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5 finalized to the induction, maintenance, and amplification of eosinophilic inflammation. Therefore, IL-5 is a suitable target for add-on biological therapies based on either IL-5 inhibition (mepolizumab, reslizumab) or blockade of its receptor (benralizumab). These modern treatments can result in being definitely beneficial for patients with severe type 2 (T2)-high eosinophilic asthma, refractory to conventional anti-inflammatory drugs such as inhaled and even systemic corticosteroids.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Felice Rivellese, Queen Mary University of London, United Kingdom
This article was submitted to Clinical and Translational Physiology, a section of the journal Frontiers in Physiology
Reviewed by: Janos Paloczi, National Institutes of Health (NIH), United States; Mario Sanchez-Borges, El Ávila Clinic, Venezuela
ISSN:1664-042X
1664-042X
DOI:10.3389/fphys.2019.01514